Business Wire

RoboSense Market Share Ranks 1st in China, 2nd Worldwide: Yole 2021 Global LiDAR Industry Report

23.9.2021 15:30:00 EEST | Business Wire | Press release

Share

RoboSense LiDAR, the leading Smart LiDAR Sensor provider, boasts 10 percent of the market share worldwide, ranking first in China and second globally, according to the “LiDAR for Automotive and Industrial Applications Report 2021” from Yole Développement, an international market research and strategic consultancy. The report covers the market share of automotive and industrial applications of over ten leading LiDAR companies worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005530/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

LiDAR design wins*-RoboSense boasts 10% of the market share worldwide, ranking 1st in China and 2nd globally (Photo: Business Wire)

RoboSense has been designated as an official long-term partner for many auto companies, and receiving orders for its RS-LiDAR-M1 (M1), RoboSense’s second-generation solid-state LiDAR, for a diverse range of mass-produced models since July 2020. These orders cover traditional automobile manufacturers and a supercar brand. Among them, GAC-Aion officially announced its plans to equip multiple models with RoboSense LiDAR in July this year.

The report also noted that mechanical LiDAR systems, including rotary and rotating mirror systems, have been losing market share since 2020 due to cost and reliability issues. It goes on to state that second-generation MEMS Smart LiDAR systems are entering the mainstream as its technology matures and cost gets more competitive.

World's first mass-produced automotive-grade solid-state LiDAR

RoboSense’s M1 employs advanced MEMS technologies. Launched in 2016 and with a demo prototype on the way next year, M1 was first shown at the International Consumer Electronics Show (CES) in 2018 and won two CES Innovation Awards in 2019 and 2020.

With over five years of research and dozens of upgrades, M1 became the first product to have a mass-production version finalized. RoboSense began mass-produced automotive-grade production of M1 in Q2 2021, and has since delivered over ten batches for models through its long-term automobile manufacturer partnerships.

Exclusive smart “GAZE” functionalities

M1 boasts an exclusive smart functionality named “GAZE”, which dynamically improves resolution and frame rate based on the environment, enabling vehicles to zoom in and out and augmenting their perception.

M1 enhances central resolution and extends the range of identification from 150 to 200 meters on highways, so that the vehicle can detect distant road conditions earlier. On city roads, M1 increases the frame rate from 10Hz to 20Hz and scans obstacles – such as pedestrians, electric bicycles and traffic jams – at a higher frequency for stronger near-field detection.

A multi-sensor, LiDAR-centric solution is key for accuracy and detection safety, whose reliability is known as the first step towards safe smart mobility. As Chinese LiDAR companies continue making breakthroughs in the global march towards smart mobility, RoboSense has become a leader in China and will continue in its commitment to innovate and supply the global intelligent automotive value chain with LiDAR solutions, accelerating the evolution of smart mobility.

About Yole Développement ( www.yole.fr

Yole Développement provides market research, technology analysis, strategy consulting, targeted media, and financial advisory services. With a strong focus on emerging applications using silicon and/or micro manufacturing since 1998, Yole Développement has expanded to include more than 80 collaborators worldwide.

About RoboSense (www.robosense.ai):

RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. The company's mission is to innovate outstanding hardware and artificial intelligence capabilities to create smart solutions that enable robots, including vehicles, to have perception capabilities superior to humans.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Grace Ye
RoboSense PR Manager
grace.ye@robosense.cn

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye